Nicholas J. Robert

20.9k total citations · 4 hit papers
181 papers, 10.0k citations indexed

About

Nicholas J. Robert is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Nicholas J. Robert has authored 181 papers receiving a total of 10.0k indexed citations (citations by other indexed papers that have themselves been cited), including 112 papers in Oncology, 87 papers in Cancer Research and 58 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Nicholas J. Robert's work include Breast Cancer Treatment Studies (62 papers), Cancer Treatment and Pharmacology (61 papers) and HER2/EGFR in Cancer Research (43 papers). Nicholas J. Robert is often cited by papers focused on Breast Cancer Treatment Studies (62 papers), Cancer Treatment and Pharmacology (61 papers) and HER2/EGFR in Cancer Research (43 papers). Nicholas J. Robert collaborates with scholars based in United States, Canada and France. Nicholas J. Robert's co-authors include Dennis J. Slamon, Melody Cobleigh, Charles L. Vogel, Debu Tripathy, Louis Fehrenbacher, Steven Shak, Virginia Paton, Suzy Scholl, Janet Wolter and Edith A. Perez and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Nicholas J. Robert

170 papers receiving 9.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

1999 2.2k citations Melody Cobleigh, Nicholas J. Robert et al. Journal of Clinical Oncology profile →
Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17

2005 818 citations Silvana Martino, Nicholas J. Robert et al. JNCI Journal of the National Cancer Institute profile →
RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

2011 766 citations Nicholas J. Robert, John A. Glaspy et al. Journal of Clinical Oncology profile →
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years

2016 411 citations Kathleen I. Pritchard, Nicholas J. Robert et al. profile →

Peers

Countries citing papers authored by Nicholas J. Robert

Since Specialization

Citations

This map shows the geographic impact of Nicholas J. Robert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicholas J. Robert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicholas J. Robert more than expected).

Fields of papers citing papers by Nicholas J. Robert

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicholas J. Robert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicholas J. Robert. The network helps show where Nicholas J. Robert may publish in the future.

Co-authorship network of co-authors of Nicholas J. Robert

This figure shows the co-authorship network connecting the top 25 collaborators of Nicholas J. Robert. A scholar is included among the top collaborators of Nicholas J. Robert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicholas J. Robert. Nicholas J. Robert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Real-world comparative effectiveness of palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer 2024 ·Future Oncology ·Nicholas J. Robert, Connie Chen, Sindy Kim, Zhe Zhang, Kathleen M. Aguilar, Yunfei Wang, Benjamin Li, Michael Gaffney, Xin Huang, Lynn McRoy	1
2	Biomarker testing in early-stage NSCLC: Results from the MYLUNG Consortium. 2024 ·Journal of Clinical Oncology ·(unknown), James E. Butrynski, John C. Paschold, Patrick J. Ward, David Waterhouse, Alexander I. Spira, (unknown), David Hakimian, Robert M. Jotte, Timothy Larson, Michael W. Meshad, (unknown), Donald Richards, Marcus A. Neubauer, Nicholas J. Robert, (unknown), (unknown), Robert L. Coleman, David R. Spigel	1
3	Health equity principles for oncology real world evidence studies 2024 ·The Oncologist ·(unknown), Henry Asante Antwi, Nicholas J. Robert, (unknown), Amy K. O’Sullivan, C. Daniel Mullins	0
4	The Evolution of Treatment Patterns for Chronic Lymphocytic Leukemia (CLL): Trends in the US Community Oncology Setting from 2015 to 2024 2024 ·Blood ·Zhaohui Su, (unknown), Jessica K. Paulus, Nicholas J. Robert, (unknown)	1
5	Real-World Use of Positron Emission Tomography-Computed Tomography and Reported Deauville Scores in Advanced-Stage Classic Hodgkin Lymphoma: A Community Oncology Practice Perspective 2023 ·JCO Oncology Practice ·Christopher A. Yasenchak, (unknown), (unknown), Michelle A. Fanale, Nicholas J. Robert, Ding Sheng He, (unknown)	0
6	Real‐world outcomes of 18,186 metastatic solid tumor outpatients: Baseline blood cell counts correlate with survival after immune checkpoint inhibitor therapy 2023 ·Cancer Medicine ·Jerome H. Goldschmidt, (unknown), Philip K. Chan, Liwei Chen, Nicholas J. Robert, (unknown), (unknown), (unknown), Edwin P. Rock, Hillard M. Lazarus	14
7	Feasibility of Using Oncology-Specific Electronic Health Record (EHR) Data to Emulate Clinical Trial Eligibility Criteria 2023 ·SHILAP Revista de lepidopterología ·Thomas W. Wilson, (unknown), (unknown), Nicholas J. Robert, Janet L. Espirito, E. Susan Amirian	0
8	Real‐World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma 2022 ·Cancer Medicine ·Wolfram E. Samlowski, Nicholas J. Robert, Liwei Chen, Brad Schenkel, Catherine Davis, Andriy Moshyk, Srividya Kotapati, (unknown), Jeffrey S. Weber	3
9	Oncology Drug Effectiveness from Electronic Health Record Data Calibrated Against RCT Evidence: The PARSIFAL Trial Emulation 2022 ·Clinical Epidemiology ·(unknown), Jessica C. Young, Deborah Schrag, Kueiyu Joshua Lin, Nicholas J. Robert, Sebastian Schneeweiß	5
10	Practice patterns among oncologists participating in the oncology care model after three years 2021 ·Journal of Cancer Policy ·(unknown), Lalan S. Wilfong, Jennifer R. Frytak, Nicholas J. Robert	1
11	Treatment Patterns and Outcomes of Patients with Relapsed or Refractory Follicular Lymphoma Treated with Idelalisib in a Community Oncology Setting 2019 ·Blood ·David Andorsky, Rebecca J. Chan, (unknown), Bianca B. Ruzicka, Nicholas J. Robert, Farrukh T. Awan	2
12	Assessment ofERBB2/HER2Status inHER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines 2018 ·JAMA Oncology ·Michael F. Press, José A. Seoane, Christina Curtis, Emmanuel Quinaux, Roberta Guzman, Guido Sauter, W. Eiermann, John R. Mackey, Nicholas J. Robert, Tadeusz Pieńkowski, John Crown, Miguel Martín, Vicente Valero, Valerie Bée, Yanling Ma, Ivonne Villalobos, Dennis J. Slamon	25
13	PTEN Loss Is Associated with Worse Outcome in HER2 -Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance 2015 ·Clinical Cancer Research ·Howard M. Stern, Humphrey Gardner, Tomasz Burzykowski, Wafaa Elatre, Carol O’Brien, Mark R. Lackner, Gary A. Pestano, Angela Santiago, Ivonne Villalobos, W. Eiermann, Tadeusz Pieńkowski, Miguel Martín, Nicholas J. Robert, John Crown, Paolo Nucíforo, Valerie Bée, John R. Mackey, Dennis J. Slamon, Michael F. Press	57
14	Health-Related Quality of Life With Adjuvant Docetaxel- and Trastuzumab-Based Regimens in Patients with Node-Positive and High-Risk Node-Negative, HER2-Positive Early Breast Cancer: Results from the BCIRG 006 Study 2013 ·The Oncologist ·Heather‐Jane Au, W. Eiermann, Nicholas J. Robert, Tadeusz Pieńkowski, John Crown, Miguel Martín, Marek Pawlicki, Arlene Chan, John R. Mackey, John A. Glaspy, Tamás Pintér, Mei-Ching Liu, Tommy� Fornander, Sandeep Sehdev, Jean-Marc Ferrero, Valerie Bée, Maria Santana, Dave P. Miller, Deepa Lalla, Dennis J. Slamon	19
15	Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole 2012 ·Annals of Oncology ·Paul E. Goss, J. N. Ingle, Silvana Martino, Nicholas J. Robert, Hyman B. Muss, Robert B. Livingston, Nancy E. Davidson, Edith A. Perez, Yanin Chávarri-Guerra, David Cameron, Kathleen I. Pritchard, Timothy J. Whelan, L. E. Shepherd, Dongsheng Tu	60
16	Phase II Study of Weekly Albumin-Bound Paclitaxel for Patients with Metastatic Breast Cancer Heavily Pretreated with Taxanes 2007 ·Clinical Breast Cancer ·Joanne L. Blum, Michael A. Savin, Gerald M. Edelman, John Pippen, Nicholas J. Robert, (unknown), Robert Kirby, Alicia Clawson, Joyce O’Shaughnessy	136
17	Randomized Phase III Study of Trastuzumab, Paclitaxel, and Carboplatin Compared With Trastuzumab and Paclitaxel in Women With HER-2–Overexpressing Metastatic Breast Cancer 2006 ·Journal of Clinical Oncology ·Nicholas J. Robert, Brian Leyland‐Jones, Lina Asmar, Robert J. Belt, D. Ilegbodu, David Loesch, Robert N. Raju, Elizabeth Valentine, Robert M. Sayre, Melody Cobleigh, Kathy S. Albain, (unknown), Lea Fuchs, Dennis J. Slamon	342
18	Prediction of Node-Negative Breast Cancer Outcome by Histologic Grading and S-Phase Analysis by Flow Cytometry 2001 ·American Journal of Clinical Oncology ·David L. Page, Robert P. Gray, D. Craig Allred, Lynn G. Dressler, Alan K. Hatfield, Silvana Martino, Nicholas J. Robert, William C. Wood	43
19	21-Day Oral Etoposide for Metastatic Breast Cancer 2000 ·American Journal of Clinical Oncology ·Thomas J. Saphner, Edie Weller, Douglass C. Tormey, Kishan J. Pandya, Carla I. Falkson, (unknown), Nicholas J. Robert	19
20	Defective Estrogen Receptors in Human Mammary Cancers: Their Significance in Defining Hormone Dependence1 1988 ·JNCI Journal of the National Cancer Institute ·Shanthi Raam, Nicholas J. Robert, Christopher A. Pappas, H Tamura	32

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact